Gene-Editing Trailblazers Launch New Venture for Custom Treatments

An infant named KJ recently experienced the life-saving power of a custom-made treatment. Developed in a mere six months, this gene-editing therapy addressed a unique genetic mutation that led to dangerous ammonia accumulation in his body. Thanks to this innovative treatment, KJ was able to leave the hospital in June, his life no longer in danger.

Inspired by successes like KJ’s, Aurora Therapeutics—a pioneering startup co-founded by renowned gene-editing expert and Nobel laureate Jennifer Doudna—plans to expand the availability of personalized treatments for individuals with rare genetic disorders. Doudna is a key inventor of the transformative CRISPR technology, which earned her the Nobel Prize in 2020.

Aurora is set to leverage a recently established FDA regulatory framework introduced by officials, including Marty Makary and Vinay Prasad, focusing on rare and fatal diseases. Known as the 'plausible mechanism pathway,' this scheme enables regulatory approval based on data from a minimal number of patients, facilitating expedited treatment availability.

While conventional drug approval processes necessitate extensive trials involving hundreds or thousands of patients, rare disease cases often struggle to meet such quotas due to limited patient numbers. This new FDA pathway offers a solution by allowing the certification of treatments when large-scale trials aren’t feasible.

The strategic advantage lies in the FDA’s willingness to authorize marketing after witnessing success in multiple patients with custom therapies. Companies like Aurora can then utilize this data to gain approval for similar treatments derived from the foundational technology, streamlining the path to market.

Aurora’s initial concentration will be on phenylketonuria (PKU), a metabolic condition detectable at birth that results in harmful levels of phenylalanine in the bloodstream. Managing PKU requires patients to adhere to a rigorous low-protein diet, critical for preventing severe cognitive impairments if untreated in early life.

Aurora Therapeutics CEO Edward Kaye, also a pediatric neurologist, recognizes the therapy's broad potential. The challenge is PKU's vast genetic diversity, with over a thousand distinct mutations contributing to the disorder.

CRISPR technology operates by guiding RNA molecules to specific genomic sites, akin to a GPS directing to a planned destination. Baby KJ’s treatment was possible because researchers crafted a guide RNA targeting his unique mutation, emphasizing the personalized nature of such interventions.

Aurora aims to tailor PKU treatments by modifying the guide RNA to address different mutations. Previously, such variations would be treated as entirely new drugs, each requiring separate trial processes. Now, Aurora can implement a universal platform for a spectrum of PKU mutations, minimizing bureaucratic hurdles.

With base editing—a refined form of CRISPR—the company intends to streamline therapy design and production, ensuring efficiency across its operations. Aurora's commitment is symbolized by their ethos of leaving no mutation untreated.

The Innovative Genomics Institute, also founded by Doudna, will continue to craft personalized therapies for very rare disorders in children. Concurrently, clinical trials at the Children’s Hospital of Philadelphia and Penn Medicine aim to apply the gene-editing techniques used on KJ to other rare diseases. Establishing Aurora was crucial for scaling these treatments to reach a broader patient base.

Despite CRISPR's transformative promise, the path has been challenging, with some companies downsizing or closing. To date, the only commercial CRISPR therapy is Casgevy, launched at $2.2 million for sickle cell disease and beta thalassemia.

Aurora’s co-founder Fyodor Urnov remains optimistic, believing the gene-editing field is poised to mature. He foresees a future where bespoke CRISPR solutions are readily accessible, envisioning widespread use in as few as three to four years.